Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. by Kersemaekers, A. M. et al.
British Joumal ofCancer(1998) 77(2), 192-200
© 1998 Cancer Research Campaign
Loss of heterozygosity for defined regions on
chromosomes 3, 11 and 17 in carcinomas of the
uterine cervix
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Summary Loss of heterozygosity (LOH) frequently occurs in squamous cell carcinomas of the uterine cervix and indicates the probable sites
of tumour-suppressor genes that play a role in the development of this tumour. To define the localization of these tumour-suppressor genes,
we studied loss of heterozygosity in 64 invasive cervical carcinomas (stage IB and IIA) using the polymerase chain reaction with 24 primers
for polymorphic repeats of known chromosomal localization. Chromosomes 3, 11, 13, 16 and 17, in particular, were studied. LOH was
frequently found on chromosome 11, in particular at 11q22 (46%) and 11q23.3 (43%). LOH on chromosome 11p was not frequent. On
chromosome 17p13.3, a marker (Dl7S513) distal to p53 showed 38% LOH, whereas p53 itself showed only 20% LOH. On the short arm of
chromosome 3, LOH was frequently found (41%) at 3p21.1. The f-catenin gene is located in this chromosomal region. Therefore, expression
of f-catenin protein was studied in 39 cases using immunohistochemistry. Staining of 1-catenin at the plasma membrane of tumour cells was
present in 38 cases and completely absent in only one case. The tumour-suppressor gene on chromosome 3p21.1 may be ,B-catenin in this
one case, but (an)other tumour-suppressor gene(s) must also be present in this region. For the other chromosomes studied, 13q (BRCA-2)
and 16q (E-cadherin), only sporadic losses (< 15% of cases) were found. Expression of E-cadherin was found in all of 37 cases but in six
cases the staining was very weak. No correlation was found between clinical and histological parameters and losses on chromosome 3p, 11q
and 17p. In addition to LOH, microsatellite instability was found in one tumour for almost all loci and in eight tumours for one to three loci. In
conclusion, we have identified three loci with frequent LOH, which may harbour new tumour-suppressor genes, and found microsatellite
instability in 14% of cervical carcinomas.
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The involvement of human papillomavirus (HPV) in the develop-
ment of carcinomas of the uterine cervix has been firmly estab-
lished. Because HPV infection does not always lead to cervical
cancer, other genetic alterations must also play a role in tumour
development. Loss ofheterozygosity (LOH), pointing to a role for
tumour-suppressor genes, oncogene amplification and point muta-
tions are all thought to be involved, but there is as yet no complete
picture of the relative role for each of these genetic changes in
cervical carcinomas. To play a role in tumorigenesis, both copies
of a tumour-suppressor gene have to be inactivated. Usually, one
allele is lost by a small inactivating mutation and the second by
loss ofheterozygosity. Loss of one allele in a chromosome region
may therefore point to the presence ofatumour-suppressor gene in
that region. Such chromosome losses can be detected by polymor-
phic markers. Different studies have reported a high incidence of
LOH on chromosomes 3p, lIp and 1 lq. However, a detailed dele-
tion map ofthese areas has not been made yet.
Seven different groups (Yokota et al, 1989; Chung et al, 1992;
Jones and Nakamura, 1992; Kohno etal, 1993; Karlsen etal, 1994;
Mitra et al, 1994; Mullokandov et al, 1996; Rader et al, 1996)
found LOH on chromosome 3 in cervical carcinomas. The
regions mapped by these investigators include 3p2l-p22, where
Received 12 February 1997
Revised 1 July 1997
Accepted8July 1997
Correspondence to: MJ van de Vijver
the ,-catenin gene is located (Kraus et al 1994; Bailey et al, 1995;
Hengel et al, 1995; Trent et al, 1995; Nollet et al, 1996). O-Catenin
is a structural mediator for the attachment ofthe cytoskeletal actin
filaments to cellular adhesion molecules, i.e. cadherins, in partic-
ular E-cadherin (Jou et al 1995; Kawanishi et al, 1995; Rubinfeld
et al, 1995). O-Catenin alsocomplexes with the APC gene product,
a tumour-suppressor gene mutated in hereditary polyposis coli and
sporadic colorectal tumours (Rubinfeld et al, 1993; Su et al, 1993;
Hulsken et al, 1994). In normal cells, APC binds together with
GSK-3, to ,-catenin and degrades it. O-Catenin can be deregu-
lated by mutations in APC or inP-catenin itself. This results in the
accumulation of ,-catenin, activating its role in signalling
(Korinek et al, 1997; Morin et al, 1997; Rubinfeld et al, 1997).
The involvement ofchromosome 11 in cervical cancer has been
reported by several groups. Hampton et al (1994) found the
smallest region ofoverlapping LOH at 1 lq22-24. Bethwaite et al
(1995) found LOH on 1 1q23, but only with one marker in this
region. Misra and Saxon (Misra and Srivatsan, 1989; Saxon et al,
1986) used HeLa cells, which had lost part of chromosome 11, to
fuse them with fibroblast hybrids that contained part or all ofchro-
mosome 11. By transferring a normal complete copy of chromo-
some 11, the HeLa cells became non-tumorigenic. This suggests
that chromosome 11 harbours genes that are involved in the
suppression ofHeLa cell tumorigenicity.
Many investigators (Kaelbling et al, 1992; Mitra et al, 1994;
Havre et al, 1995; Hoppe-Seyler and Butz, 1995; Mansur et al,
1995; Mullokandov et al, 1996) have studied the short arm of
chromosome 17 for the p53 gene, which may be involved in
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Table 1 Frequency of LOH observed with 24 PCR primers for
chromosomes 3,11,13,16 and 17 in 64 cervical cancers
Locus Map position Cases studied LOH (%)
(informative cases)
D3S1270 3pter-p25 61 (38) 7 (18%)
D3S1211 3p24.2-p22 55 (29) 6 (20%)
D3S11 3p23 62 (39) 5 (13%)
D3S1768 3p23 57 (40) 11 (28%)
J-catenin 3p22 62 (35) 13 (37%)
D3S2456 3p21 58 (44) 18 (41%)
D3S1289 3p21.2-p21.1 57(43) 17 (40%)
D3S196 3q27-q28 61 (43) 3 (7%)
D11S865 11p15.1 59(47) 6 (13%)
D11S875 11p15.4-p13 63(46) 3 (7%)
D11S554 11p12-p11.2 47(33) 4 (12%)
D11S35 11q22 57 (41) 19 (46%)
DRD-2 11q23.1 61 (21) 5(24%)
D11S528 11q23.3 63(47) 20 (43%)
D17S513 17p13.3 62 (42) 16 (38%)
D17S1537 17p13.3 58 (31) 10 (32%)
TP53 17p13.1 63 (44) 9 (20%)
D17S520 17p12 58 (41) 4 (10%)
D17S578 17q11.2 53(28) 2 (7%)
D17S855 17q21 (BRCA1) 57 (41) 2 (4%)
D13S153 13q1 3-14 (RB) 61 (50) 2 (4%)
D13S289 13q12.3 (BRCA2) 62 (44) 6 (13%)
D16S752 16q22.1 57 (47) 7 (14%)
D16S2624 16q22.1 56 (47) 5 (10%)
tumours were clinically staged as class IA (2), IB (48) and IIA
(14), and were treated with radical hysterectomy. The ages of the
patients ranged from 22 to 76 years with a median of45 years. All
material consisted of formalin-fixed paraffin-embedded tissue.
Haematoxylin & eosin sections were screened and tissue blocks
were selected if they contained 50% or more tumour tissue.
Constitutional DNA was extracted from the uterus wall, which did
not contain tumour tissue.
DNA extraction
DNA extraction was performed according to the protocol described
by Isola et al (1994) with some adjustments. Ten 16-jim sections
were cut from the tissue blocks. Tumour-rich areas were identified
using a consecutive haematoxylin and eosin-stained section for
guidance. The areathatcontained 50% ormore tumourcells was cut
away with a clean knife and put in sterile microcentrifuge tubes.
This enrichment resulted in isolation of DNA from material
containing at least 50% tumour cells. The tissue was deparaffinated
in xylene, centrifuged and subsequently washed twice in 100%
ethanol. DNA was isolatedby incubation for72 h at55°C in 1 ml of
isolation buffer containing 100 mm sodium chloride, 10 mm Tris-
HCI (pH 8), 25 mm EDTA (pH 8) and 0.5% sodium dodecyl
sulphate. An aliquot (30 ,ul) of proteinase K (10jg il-1) was then
added to the mixture, and fresh 15-jl aliquots ofproteinase K were
added after 24 and 48 h. DNA was extracted by phenol/chloroform
and precipitated with 1 ml of 100% ethanol, 20jg ml-' glycogen
and 250 jil 7.5 M ammonium actinium. DNA was dissolved in Tris-
EDTA (10 mm Tris, 0.1 mm EDTA, pH 7.6).
cervical carcinomas through its interaction with HPV-E6 oncopro-
teins. p53 point mutations are infrequent (< 10%) in clinical
samples of squamous cell carcinomas of the uterine cervix,
whereas p53 point mutations were seen more often in adenocarci-
noma (30%) (Fujita et al, 1992; Jiko et al, 1994; Schneider et al,
1994). Park et al (1995) detected LOH at l7pl3.3 in eight (40%)
out of 20 heterozygous cervical carcinomas, with at least one of
the two markers D17S34 or D17S5. This region also shows a high
incidence of LOH in other tumours, such as tumours of the
bladder, ovary and breast (Cornelis et al, 1994; Morris et al, 1995).
In this study, we analysed a series of 64 squamous cervical
carcinomas for the presence of LOH on chromosomes 3, 11, 13,
16, and 17 for 24 polymorphic repeats. Chromosomes 3 and 11
were studied in more detail, using an extra set offourpolymorphic
DNA markers on chromosome 3p, and nine on chromosome 1lq,
to determine the smallest region of overlap. We also studied by
immunohistochemistry the expression of the protein products of
two candidate (tumour-suppressor) genes on chromosome 3p and
16q, the I-catenin and E-cadherin gene. All allelic losses found on
chromosomes 3, 11 and 17 were correlated to each other and with
clinical parameters, including FIGO stage, lymph node status and
histological parameters.
MATERIALS AND METHODS
Materials
From 60 patients with squamous cell carcinoma and four patients
with adenocarcinoma of the uterine cervix operated on between
1984 and 1995, tissue blocks were retrieved from the archives of
the Department of Pathology, University Hospital Leiden. The
Polymerase chain reaction (PCR) technique
Primers for polymorphic repeats (Table 1, mostly CA repeats and
some tetranucleotide repeats) were chosen on the basis of their
heterozygosity percentage, location and allele length from the
genome database. The intragenic ,B-catenin primers were kindly
provided by F Nollet, University of Ghent, Belgium. A standard
PCR was carried out in a 12-jil reaction volume containing 10 ng
ofDNA, 5 pmol ofeach primer, 2 mm dNTP-C, 0.1 mg ml-1 BSA,
Taq polymerase buffer (containing 10 mmol Tris, 1.5 mm magne-
sium chloride, 50 mm potassium chloride, 0.01% (w/v) gelatin,
0.1% Triton), 0.06units SuperTaq polymerase (HTBiotechnology,
Cambridge), and 1 jiCi [a-32P]-CTP. The amplification reactions
were carried out for 33 cycles at 55°C annealing temperature. The
PCR products were denatured in formamide, electrophoresed on a
6% denaturing polyacrylamide gel, and visualized by auto-
radiography for 14-18 h at room temperature. Absence of or a
very strong decrease in signal intensity of one allele in tumour
DNA compared with constitutional DNA by visual examination
was considered evidence for LOH. When a decrease in signal
intensity was not convincing, the cases were measured on a
Molecular Dynamics Phosphorlmager 445SI. Molecular
Dynamics ImageQuant Software was used for quantification of
PCR products. An allelic imbalance factor was calculated by the
quotient of the peak ratios from constitutional and tumour DNA
(Ni:N2/T1:T2). In cases where the allele ratio calculated
by this equation was beneath 1.00, we converted the ratio to
l/[Nl:N2/T1:T2]. An allelic imbalance of 1.8 or lower is inter-
preted as retention, whereas an allelic imbalance of 1.8 orhigheris
considered as a LOH event (Devilee et al, 1994). Loci showing
microsatellite instability were not scored as LOH.
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Figure 1 Analysis of microsatellite markers on chromosome 3,
chromosome*1 and chromosome 17 in different tumours. N, normal DNA;
T, tumour DNA. Patient identification numbers are shown at the left.
Microsatellite markers used are shown above each pair of lanes. LOH is
indicated with arrows. The imbalance factor as assessed using the
phosphorimager is given for each case
In some cases no PCR product could be obtained, even after
repeated attempts. These were excluded for these polymorphic
markers.
Immunohistochemistry
Irnrunohistochemical detection of 0-catenin and E-cadherin was
performed on 39 samples included in the LOH study. Incubations
were performed at room temperature unless stated otherwise.
Phosphate-buffered saline (PBS) with 1% BSA was used as
diluent for all antibodies. All washes consisted of 3 x 5 min.
Paraffin sections were deparaffinized, rehydrated and endogenous
peroxidase was quenched with 0.3% hydrogen peroxide in
methanol for 20 mmn. Before incubation with the primary anti-
bodies the slides were subjected to antigen retrieval using aboiling
solution of0.01 M citrate bufferpH 6.0 (Cattoretti et al, 1993) in a
microwave oven at 700 W and cooled down to room temperature
in citrate buffer for 2 h. After washing in PBS, an ovemight incu-
bation followed with mouse monoclonals anti-human ,B-catenin
(1:4000, Transduction Laboratories) and anti-E-cadherin, clone
HECD-1 (1:500, Zymed). Biotin-labelled rabbit anti-mouse
immunoglobulins and a biotinylated HRP-streptavidin complex
(both Dako) were subsequently applied for 30 min each with
washes in PBS in between. A 0.05% solution ofdiaminobenzidine
(Sigma) with 0.0015% hydrogen peroxide was applied for 10 min
to visualize the immune aggregates. Mayers' haematoxylin was
used for counterstaining ofthe slides.
Brown staining of the plasma membrane indicated a positive
staining for both antibodies. Normal squamous epithelium, when
present, served as an internal positive control. Omitting the
primary antibody on serial slides served as a negative control.
Immunohistochemical stainings of P-catenin and E-cadherin
were scored semiquantitatively. The percentage of tumour cells
stained positive were scored as 0 = no positive tumour cells; 1 =
1-25%; 2 = 26-50%; 3 = 51-75%; 4 = 76-100%. The intensity
was estimated in comparison with the control and scored as 0 =
absence of staining; 1 = weak staining; 2 = moderate staining; 3 =
strong staining. A final score was calculated by adding the scores
for percentage-positive cells and intensity, resulting in a score of0
orranging from 2 to 7. This final score is categorized into: negative
(0), weak (2-3) or strong (4-7).
Statistical analysis
The percentages loss on 3p, 1 q and 17p were correlated to each
other and to FIGO stage, lymphnode positivity, tumour size,
vasoinvasion and histology. With the chi-square test these percent-
ages were evaluated.
RESULTS
LOH analysis on chromosomes 3, 11, 17, 13 and 16
All 64 carcinomas were analysed for the same polymorphic
markers on chromosome 3, 11, 17, 13 and 16. Table 1 shows
the list of polymorphic markers used, their map positions, the
proportion of informative cases among tumours studied and the
frequency of LOH at each locus. Figure 1 shows representative
films demonstrating LOH at several loci. Among the loci that had
LOH, the frequency varied widely, ranging from 4% [D17S855
(BRCA1)], D13S153 (RB)] on chromosome 17q and 13q to 46%
(DlIS35) on chromosome llq. Chromosome arms llq, 3p, and
17p had LOH in more than 25% of tumours. Figure 2 shows the
LOH patterns found on chromosomes 3, 11 and 17. Nine tumours
did not have LOH on any of the chromosome arms studied.
Additional markers were used forthose chromosome arms that had
frequent LOH, i.e. chromosomes 3 and 11.
Chromosome 3p
On the short arm ofchromosome 3, frequent LOH (40%) was found
at 3p2l.1 (D3S1289). The smallest region of overlap was on
3p2l-3p23. Using the additional markers in this region we could
decrease the smallest region of overlap for LOH between an intra-
genic marker in [B-catenin (F Nollet et al, personal communication)
and D3S1289. Thedistance between these markers is approximately
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Figure 2 Schematic representation of the regions on chromosomes 3, 11 and 17 with LOH. Patient identification numbers are above each row of symbols.
0, markershowing retention; 0, markershowing LOH; -, markerhomozygous (notinformative). Open spaces, notinvestigated. mi, microsatellite instability
15 cM. Part of the f-catenin gene is still in this region of smallest The LOH pattern revealed three different regions with a high
overlap. percentage deletion encompassing Dl S35 on lq22.1, Dl S938
on 1 1q22.3 and Dl lS528 on 1 1q23.3 (see Figure 3).
Chromosome 11q
The 34 tumours with LOH for chromosome lq were tested for Chromosome 17p
additional markers. Figure 3 shows the results of this screening. On chromosome 17pl3.3 a marker (D17S513) distal to the p53
Among the markers tested, LOH was most frequent in these 34 tumour-suppressor gene had 38% LOH. TP53, a marker within
tumours at Dl 1S35 (79%), Dl 1S938 (71%) and Dl 1S528 (74%). the p53 coding region, had 20% LOH. In ten cases there is a
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Figure 3 Frequency of LOH observed for ten microsatellite markers for
chromosome 11 in 34 cervical cancers
Table 2 Comparison of ,-catenin and E-cadherin expression compared
with the LOH results on chromosome 3 and chromosome 16 respectively
LOH present, LOH absent,
chromosome 3 chromosome 3
O-Catenin strong staining 19 13
,B-Catenin weak staining 5 1
,B-Catenin loss of staining 1 0
LOH present LOH absent
chromosome 16 chromosome 16
E-cadherin strong staining 2 29
E-cadherin weak staining 3 3
E-cadherin loss of staining 0 0
breakpoint between D17S513 and TP53. One other marker in this
area, D17S1537, was tested and had 32% LOH. This marker has
not been mapped precisely, but based on our results it is most
likely located distal to D17S513.
Microsatellite instability
In addition to LOH, microsatellite instability was observed in 9 out
of 64 cases ranging from 1-15 affected loci in 24 microsatellite
markers, resulting in increased or decreased size of one or both
alleles. All cases also had LOH at other loci. Two had microsatel-
lite instability at three loci, whereas six cases were affected at only
one locus. The remaining tumour (CT73) had microsatellite
instability for almost all loci, except for one locus, D16S752,
which had LOH (Figure 4).
,-Catenin and E-cadherin expression
The 0-catenin gene is located on chromosome 3p2l and an intra-
genic polymorphic 0-catenin microsatellite marker shows frequent
LOH. Therefore, P-catenin is a potential tumour-suppressor gene
in cervical carcinomas. Inactivation of the 3-catenin gene is
expected to result in loss of expression of the ,B-catenin protein,
and therefore we investigated ,B-catenin expression using immuno-
histochemistry. P-Catenin expression was strong in 32, weak in six
cases and completely negative in one case (Table 2 and Figure 5).
An inactivation of both P-catenin alleles would be expected to
result in complete loss of0-catenin expression. We conclude that
D3S1211 D13S153 D17S855 D3S1270 D11S528 D16S752
N T N T N T N T N T N T
Figure 4 Microsatellite instability in patient 73. N, normal DNA; T, tumour
DNA. Microsatellite markers used are shown above each pair of lanes.
Arrows indicate the additional bands. For marker Dl6S752 this patient had
LOH (arrow)
P-catenin inactivation is not frequent in cervical carcinomas and
that for most cases in which chromosome 3p2l1.1 is lost, another
tumour-suppressor gene may be inactivated. The one case with
complete loss of *-catenin expression did show LOH on 3p21.1,
and in this tumour the other .-catenin allele may be mutated.
P-Catenin associates with E-cadherin, which is located on chro-
mosome 16q22.l. Therefore E-cadherin can be a candidate
tumour-suppressor gene for the tumours showing LOH on chro-
mosome 16, as has been established in other tumour types (Berx et
al, 1995). E-cadherin expression was also studied in this tumour
series. Strong E-cadherin expression was found in 31 of 37 cases,
and six cases had weak expression. Complete absence of E-
cadherin expression was never observed. There was no association
between the level ofP3-catenin and E-cadherin expression.
Correlation with tumour characteristics
In Table 3 the different clinical and histological parameters are
correlated to losses on chromosome 3p, llq and 17p. As can be
seen in Table 3, the only significant correlation was forhistological
type and loss on chromosome 3p. LOH on chromosome 3p was
observed in 54% ofsquamous carcinomas andin none ofsix adeno-
carcinomas. The LOH data were also correlated with respect to
each other, but there is no correlation between the different losses.
DISCUSSION
We have identified three chromosome regions that are likely to
harbour tumour-suppressor genes important in the tumorigenesis
of cervical cancer. Frequent LOH (41%) on chromosome 3p was
found in the region between the ,B-catenin gene and marker
D3S1289. Thus, we narrowed down the region ofLOH to approx-
imately 15 cM. The f-catenin gene is located in this smallest
region of overlap. With the intragenic marker for ,-catenin we
found 37% LOH, which points to a possible role for this gene in
cervical cancer. Ifthe 3-catenin gene would be inactivated by LOH
and mutational inactivation, complete loss of 0-catenin protein
expression is expected. This was only found in one case. Mutation
analysis by single-strand conformation polymorphism will be
performed on the one tumour that had loss of1-catenin expression
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Figure 5 Immunohistochemical staining for 3-catenin and E-cadherin. Two different tumours are shown. (A) Strong membrane staining for 3-catenin.
(B) Tumour with loss of staining for P-catenin. (C) Strong membrane staining for E-cadherin. (D) Tumour with weak staining for E-cadherin. For both E-cadherin
and ,-catenin, staining is located at the plasma cell membrane. N, normal squamous epithelium; T, tumour tissue. Normal epithelium serves as an internal
positive control for both f-catenin and E-cadherin staining
and in the six cases with weak expression. In colon cancer and
melanoma, it has been described that B-catenin can be stabilized
and become unbound to APC by mutations in the tumour-
suppressor gene APC or in ,-catenin itself. If the association
between APC and ,-catenin is released, this will promote forma-
tion of ,-catenin-Tcf complexes, which are translocated to the
nucleus and activate gene transcription.
Various groups have studied chromosome 3p in cervical carci-
nomas, and 3p21-22 was a common region ofLOH (Mullokandov
et al, 1996). The marker most used and lost in this region is D3S2.
It is located between D3S1289 andD3S1768, which we used. This
region is also frequently involved in LOH in othertumours (breast,
lung, kidney). In addition to the P-catenin gene, other candidate
(tumour-suppressor) genes are located in this area, for instance
TGM-4 (Gentile et al, 1995), which is the human prostate trans-
glutaminase type IV gene whose function has been associated with
the mammalian reproductive system and hMLH-1 (Bronner et al,
1994; Hemminki et al, 1994; Papadopolous et al, 1994), a human
DNA mismatch repair gene involved in human non-polyposis
colorectal cancer (HNPCC) families. However, LOH on 3p2l-22
is not associated with the RER phenotype. Ourresults indicate that
an as yet unidentified gene between ,-catenin and D3S1289 most
probably functions as a tumour-suppressor gene in cervical cancer
that may also be involved in other tumour types. Further mapping
will be required to identify this gene.
The E-cadherin gene is located on chromosome 16q22.1 and
is a prime mediator of cell-cell adhesion in epithelial cells. This
tumour-suppressor gene was studied because of its interaction
with the f-catenin protein. We found six cases that had weak
expression of E-cadherin; total loss of expression was not seen.
LOH for 16q22.1 was sporadically found(10-14%) in the 64 cases
studied. Others (Inoue et al, 1992; Vessey et al, 1995) have studied
the expression of E-cadherin in normal cervical epithelium, CIN
lesions, cervical carcinomas and metastases. These groups found
that there was altered expression of E-cadherin in some CIN
lesions and some tumours. The results from the different groups
and our results suggest that alterations in the E-cadherin gene are
not ofmajor importance in cervical carcinomas.
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Table 3 Losses on chromosome 3p, 11q and 17p correlated with tumour characteristics
Chromosome 3p Chromosome 11q Chromosome 17p
n Per cent loss P-value n Per cent loss P-value n Per cent loss P-value
FIGO-stage
51 51 0.62 49 51 0.51 48 42 1.00
11 13 38 12 67 11 45
Lymphnode
+ 15 60 0.50 14 57 0.98 14 21 0.11
- 48 46 46 52 44 50
Tumour size
<3 cm 31 52 0.9 31 45 0.29 30 43 0.96
>3 cm 32 47 29 62 28 39
Vasoinvasion
No 39 56 0.23 38 58 0.73 36 27 0.29
Little 32 13 1 1 45 1 1 45
High 10 40 10 50 10 20
Histology
Squamous 57 54 0.03 54 56 0.54 53 42 1.00
Adeno 6 0 6 33 5 40
We made a more specified LOH map for cervical cancer on
chromosome llq between 1IqI3.1 and llq23.3 using twelve
microsatellite markers. We have found three different markers
with frequent LOH, DllS35, DllS938 and DIIS528, but we
could not find a single smallest region of overlap. These three
markers are located on different chromosome bands. It is possible
that three different loci on this chromosome are involved in
cervical cancer. Hampton et al (1994) described about 44% loss of
the region llq22-q24 but used only five markers in this area,
which are located in the same region as the markers used by us.
Bethwaite etal (1995) used only one marker (DIlS29) in this area,
which had 30% loss. This marker is located at the same chromo-
some region as Dl S528 used in these experiments. The region
between 1lq22-q24 is also involved in other tumours, including
malignant melanoma (Tomlinson et al, 1993), breast cancer,
colorectal cancer (Keldysh et al, 1993), ovarian cancer (Foulkes et
al, 1993) and paragangliomas (Devilee et al, 1994). The STMY
gene is located near marker DlI S35 and is a candidate tumour-
suppressor gene. A candidate locus near Dl S938 is the PGL-
locus. Candidate tumour-suppressor genes near Dl1IS528 are
NCAM and CD3D.
On chromosome 17, we studied the regions containing the p53
gene and BRCA-1. 17q23, containing BRCA-1, had LOH in only
4% oftumours andis notlikely tobeofimportance incervical carci-
nomas. TP53, inthep53 gene, hadLOHin 20% oftumours whichis
in the same range found by others (Mitra et al, 1994; Mullokandov
et al, 1996). In contrast, frequent LOH was found on 17pl3.3 with
two markers D17S513 (38%) and D17S1537 (32%). Park et al
(1995) found 40% LOH with one of two markers (D17S34 and
D17S5) used on 17pl3.3. These markers are placed approximately
19 cM from our markers. This region also shows frequent LOH in a
number of different tumours, such as carcinomas of the bladder,
ovary, breast, malignant medulloblastomas, hepatocellular and
medulloblastomas (Comelis et al, 1994; Morris et al, 1995). Morris
et al (1995) identified the CRK and ABR genes in this region; these
genes are involved in signal transduction. Furthermore, Makos
Wales et al (1995) located a new candidate suppressor gene in this
region, HIC-1 (hypermethylated in cancer 1). This gene contains a
p53-binding site, andis activated by wild-typep53. Itis expressed in
normal tissues, but expressed at a lower level in tumour cells in
which itis hypermethylated (Makos Wales etal, 1995). In one study
ofbreastcancer, the independent loss of 17pl3.3 alleles was accom-
panied by increased levels of p53 mRNA, which suggests that the
17pl3.3 tumour-suppressor gene may regulate p53 expression
(Coles et al, 1990). From our results and the results of others it is
clear that a tumour-suppressor gene that is important for cervical
carcinomas mustbe present on chromosome 17pl3.3.
Recently, it was found that tumours can have a RER (replication
error) phenotype, pointing to malfunctioning of the DNA repair
and replication mechanisms. Clearly, RER-positive tumours are
defined as tumours that have microsatellite instability in at least
two out of the seven microsatellite loci (Burks et al, 1994). One
tumour in our series meets these criteria. RER is often found in
colorectal cancers, colon, endometrial (Burks et al, 1994) and
ovarian cancers (Orth et al, 1994; Liu et al, 1995). In cervical
cancer, two groups (Mitra et al, 1995; Larson et al, 1996) reported
microsatellite instability. Mitra et al (1995), reported this phenom-
enon only at a few loci on chromosome 5. Larson et al (1996)
studied three different chromosomes in 89 primary cervical
tumours and found RER+ phenotypes in 5.6% of cases. In our
series, we found nine cases (14%) that had microsatellite insta-
bility at various loci, and LOH was shown in all these cases.
In conclusion, we have provided additional evidence for the
probable presence of at least three tumour-suppressor genes in
squamous cell carcinomas ofthe uterine cervix: one at3p2l, one at
l7pl3.3 and one to possibly three at chromosome 11. We will
continue mapping the smallest region of LOH in these tumours
and analyse candidate genes present in the regions of LOH. We
have confirmed the presence of microsatellite instability in
approximately 14% ofcervical carcinomas.
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